ArticleFrontiers in oncology2026
A case report of thoracic SMARCA4-deficient undifferentiated tumor associated with brain metastases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) were considered distinct from the traditional NSCLC with SMARCA4-deficient (SMARCA4-dNSCLC) in the 5th edition of the WHO classification of thoracic tumors in 2021. Due to the low incidence rate and the lack of sufficient research, clear treatment guidelines for SMARCA4-UT are currently lacking. We report a rare case of thoracic SMARCA4-deficient undifferentiated tumor with multiple brain metastases. Following treatment with cranial metastasis radiotherapy and systemic immunotherapy combined with chemotherapy, the lesions significantly decreased in size, and the patient's symptoms improved markedly. This article retrospectively analyzed the diagnosis and treatment process of a case of SMARCA4-UT and discussed therapeutic progress and future prospects. Given the limitations of current single-drug therapy, the combined use of immunotherapy, chemotherapy, and new target drugs is an essential choice and the future direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.